New BioMedicine Price movements of the small-cap and mid-cap Biotechnology companies are generally Event-driven rather than Earnings-driven (since most of them usually do not have any earnings). Thus, noteworthy news on any of the company’s key existing/pipeline products generally results in a significant move in the respective stock price (and often in related companies). This investment rationale has yielded returns that are AT LEAST 30% higher than the S&P 500 Index since the inception of the company in 2005.
We issue daily reports that cover a specific event related to a specific drug in the company's product pipeline. Each report discusses the upcoming event, the relevant drug or device, the market opportunity for that particular product, the competitive landscape, and our expectation on the outcome of the event. The report is designed to provide a simplistic and easy to understand analysis of the event, its expected timing, and the expected outcome (Positive or Negative).
What's so special?
1. Price movement after outcome usually is very large.
2. Report covers the company pipeline and market size of each drug
in the pipeline.
3. Report provides clear understanding of the drug application.
4. Report predicts whether the scientific community will view the
event as positive or negative.
5. Opportunity for successful returns.